Announcement • Mar 05
Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant Matricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials. Announcement • Feb 27
Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors Matricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment. New Risk • Feb 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m). 
